白细胞介素-11联合生血宝治疗恶性肿瘤化疗后血小板减少的疗效观察OA

Objective To investigate the efficacy of interleukin-11 combined with Shengxuebao in the treatment of thrombocytopenia after chemotherapy for malignant tumors.Methods A total of 60 patients with malignant tumors admitted to Yifeng County People's Hospital from January 2019 to October 2023 were selected as the research objects.According to the random number table method,they were divided into study group and control group,with 30 patients in each group.The control group was treated with interleukin-11,and the study group was treated with interleukin-11 combined with Shengxuebao.The clinical efficacy,incidence of thrombocytopenia,platelet count(PC)and platelet count changes were compared between the two groups.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).The incidence of thrombocytopenia in the study group was lower than that in the control group(P<0.05).The PC level of the two groups after treatment was higher than that before treatment,and the PC level of the study group was higher than that of the control group(P<0.05).The duration of platelet count<50×109/L,the time required to recover to 70×109/L,and the time required to recover to 100×109/L in the study group were shorter than those in the control group(P<0.05).Conclusion Interleukin-11 combined with Shengxuebao is effective in the treatment of thrombocytopenia after chemotherapy for malignant tumors.It can more effectively prevent thrombocytopenia after chemotherapy for malignant tumors,and shorten the time for platelet count to return to normal.